Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Cronos Group Inc. (CRON) vs Pacira BioSciences, Inc. (PCRX)

Cronos Group Inc. and Pacira BioSciences, Inc. are both Drug Manufacturers Specialty & Generic companies. Cronos Group Inc. is the larger, with a market value of $1.2B against $1.0B — 1.2× the size. Cronos Group Inc. trades at the lower P/E: 16.7× against 71.8×. Cronos Group Inc. grew revenue faster over the last twelve months: 37.5% against 5.71%. Cronos Group Inc. has the higher net margin (20.9% vs 1.96%) and the lower return on invested capital (−0.34% vs 1.58%). Across the 22 metrics below, Cronos Group Inc. leads on 12 and Pacira BioSciences, Inc. on 10.

Valuation

Metric CRON PCRX Drug Manufacturers Specialty & Generic median
P/E 16.70 71.77 20.14
P/S 6.97 1.33 2.25
P/B 1.12 1.48 1.90
Price to free cash flow 25.24 5.52 16.54
EV/EBITDA 36.04 12.68 12.29
EV/Sales 2.53 1.75 2.56
Earnings yield 5.99% 1.39% (2.99%)
Free cash flow yield 3.96% 18.11% 0.00%

Profitability

Metric CRON PCRX Drug Manufacturers Specialty & Generic median
Gross margin 45.86% 79.21% 53.94%
Operating margin (0.96%) 2.66% 0.00%
Net margin 20.91% 1.96% 0.00%
Free cash flow margin 27.61% 24.06% 0.00%
Return on equity 3.33% 2.05% (0.40%)
Return on assets 3.18% 1.05% (3.32%)
Return on invested capital (0.34%) 1.58% 0.00%

Growth

Metric CRON PCRX Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 37.46% 5.71% 10.01%
EPS growth (last fiscal year) (118.18%) 107.44% —
Revenue growth, 5-year CAGR 25.70% 11.07% 6.74%
Net income growth, 5-year CAGR 0.00% (45.44%) 0.00%

Health

Metric CRON PCRX Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 0.54 0.05
Current ratio 16.18 5.04 2.31
Net debt to EBITDA 337.10 1.24 0.85

Dividend

Metric CRON PCRX Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric CRON PCRX Drug Manufacturers Specialty & Generic median
Market cap 1.22b 1.02b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack